Argenx presents new efgartigimod data at EULAR 2025 - PharmaTimes Rheumatology studies show promising results for Sjogren’s disease

#pharmaceuticals #Rheumatology #NeuromuscularDisease #Argenx #efgartigimod #efgartigimoddata #EULAR2025 #Sjogrensdisease #myositis #FastTrackdesignation #primarySjogrensdisease #ALKIVIAstudy #myositispatients #FcRninhibitor #UNITYtrial
pharmatimes.com/news/argenx-...